Barrick Mining Corporation Stock Price, News & Analysis

Helzberg, a subsidiary of Berkshire Hathaway (NYSE:BRK), has announced a national partnership with Big Brothers Big Sisters of America (BBBSA) ahead of Big Brothers Big Sisters Month in September 2025. The collaboration combines financial investment, volunteer engagement, and career exploration opportunities to enhance youth mentorship nationwide.

The partnership launched in Kansas City with BBBSA's Diamond Anniversary celebration at Kauffman Stadium and will continue with various events including a special gathering at the KC Current match on August 30. Helzberg's nationwide network of associates will participate in volunteer efforts including career day mentoring and Pack + Give Back events across key markets.

BioArctic (Nasdaq Stockholm: BIOA B) has entered into a significant collaboration agreement with Novartis Pharma AG to develop potential neurodegeneration treatments using BioArctic's proprietary BrainTransporter technology. The deal includes an upfront payment of $30 million to BioArctic.

Under the agreement, BioArctic will develop a new drug candidate combining their BrainTransporter technology with Novartis' proprietary antibody. If Novartis exercises their option following evaluation, they could pay up to $772 million in additional milestone payments plus mid-single digit royalties on future global sales. This marks BioArctic's third partnership utilizing their BrainTransporter platform, which enhances brain uptake of therapeutic agents through blood-brain barrier biology.

BioArctic AB (NASDAQ Stockholm: BIOA B) announced the EU launch of Leqembi®, the first therapy targeting an underlying cause of Alzheimer's disease, starting in Austria on August 25, 2025, and Germany on September 1, 2025.

The drug, approved by the European Commission in April 2025, is indicated for adult patients with mild cognitive impairment and mild dementia due to early Alzheimer's disease who are ApoE ε4 non-carriers or heterozygotes with confirmed amyloid pathology. In clinical trials, Leqembi demonstrated a 31% reduction in clinical decline at 18 months compared to placebo in the EU indicated population.

The treatment uniquely targets both amyloid plaque and protofibrils, potentially impacting tau accumulation. Common adverse reactions include infusion-related reactions (26%), ARIA-H (13%), headache (11%), and ARIA-E (9%).

BioArctic AB (NASDAQ Stockholm: BIOA B) has announced the upcoming release of its Q2 2025 financial report on August 28, 2025, at 08:00 a.m. CET. The company will host an audiocast with teleconference in English at 09:30 CET featuring CEO Gunilla Osswald, CFO Anders Martin-Löf, and other executives who will present and discuss the quarterly results.

The presentation will be accessible via webcast and teleconference, with opportunities for participants to ask questions either written or verbally. The webcast recording will be available on-demand through BioArctic's corporate website after the event.

ETQ, a division of Hexagon (HEXA), has been shortlisted for the 2025 A.I. Awards in the Best Use of AI in Manufacturing category. The recognition comes for their ETQ Reliance® Predictive Quality Analytics (PQA) solution, developed in partnership with Acerta.

The PQA solution leverages machine learning to analyze manufacturing data, detect potential defects early, and provide proactive solutions to quality issues. The AI-driven system helps manufacturers improve operational efficiency, ensure compliance, and manage risk by identifying production problems earlier and enabling faster resolution.

Integrum AB (NASDAQ: INTEG), provider of the OPRA™ Implant System, has secured the exclusive Legacy Sponsor position for the Global Collaborative Congress on Osseointegration (GCCO) annual meeting in Charlotte, North Carolina. The three-year sponsorship agreement represents the highest level of sponsorship available.

As Legacy Sponsor, Integrum will support the global limb loss community by promoting research, improving outcomes, and facilitating cross-disciplinary education in bone-anchored prosthetics. The GCCO conference brings together experts in surgical innovation, rehabilitation, prosthetics, and clinical research to advance limb loss care.

Barrick Mining (NYSE:B) has appointed former Shell CEO Ben van Beurden as Lead Independent Director, succeeding Brett Harvey who held the position since 2013. Van Beurden, who joined Barrick's Board in May 2025, brings nearly four decades of experience in energy and natural resources sectors.

During his tenure at Shell, van Beurden led the company's transformation from an oil-focused business to a diversified energy leader. He currently serves as a senior advisor at KKR, board member at Mercedes-Benz Group AG, and Chairman of Clariant. Brett Harvey, who has been on Barrick's board since 2005, will continue as a board member.

Barrick Mining (NYSE:B) reported strong Q2 2025 results with significant improvements across key metrics. Net earnings per share reached $0.47, while operating cash flow for H1 2025 increased 32% year-over-year to $2.5 billion. Free cash flow surged 107% to $770 million.

Production showed notable growth with Q2 gold output up 5% and copper production rising 34% compared to Q1. Nevada Gold Mines led with an 11% production increase, while Pueblo Viejo saw a 28% boost. The company declared a $0.15 dividend and repurchased $268 million in shares during Q2.

Key growth projects remain on track, including Reko Diq's development and Fourmile's exploration program, which could potentially double existing resources by year-end. The company maintains strong sustainability performance with a 50% reduction in lost time injuries and continues advancing responsible closure initiatives.

Barrick Mining (NYSE:B) has announced two significant shareholder returns initiatives. The company declared an enhanced Q2 2025 dividend of $0.15 per share, payable on September 15, 2025, to shareholders of record as of August 29, 2025.

Additionally, Barrick reported substantial progress in its share buyback program, having repurchased 13.50 million shares in Q2. Since the program's February 2025 announcement, the company has bought back 21.19 million shares (approximately 1.2% of outstanding shares) for a total of $411 million, with $268 million spent in Q2 alone.